Millennium Pharmaceuticals Limited

Takeda Pharmaceutical Company Limited

Mitsubishi Tanabe Pharma Corporation

Banyu Pharmaceutical Co. Ltd

Mitsubishi Pharma Corporation

Masaaki Hirose

Stepan Vyskocil

Zhan Shi

Yongbo Hu

Masanori Okaniwa

Hong Myung Lee

Tianlin Xu

Masami Miura

Terufumi Takagi

Hiroyuki Irie

Taeko Miwa

Shinobu Kuwae

Kenmi Miyano

Wataru Otani

Hideyuki Ohi

Todd B Sells

Brian Scott Freeze

Zhigen Hu

Steven P Langston

Tricia J Vos

Hiroshi Banno

Gang Li

Takashi Imada

Kenneth M Gigstad

Koji Yamada

Courtney A Cullis

Takaharu Hirayama

Hirotake Mizutani

Nobuhiko Kawanishi

Osamu Kurasawa

Hiroshi Hirai

Noriyuki Nii

Tetsuya Sugimoto

Hisashi Iwaasa

Jianping Guo

Hiroyuki Watanabe

David P Cardin

Kouta Masutani

Takashi Motoyaji

Krista E Granger

Miho Mizutani

Leo R Takaoka

Yoko Hayashi

Hiroyuki Kakei

Kaori Kamijyo

This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R, R, o, R, and Rand subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease. 

Quinoxaline compounds and uses thereof

This invention provides compounds of formula IA or IB: wherein R, R, Gand HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Heteroaryls and uses thereof

The present invention relates to a compound represented by the formula (I) or (I'): 

Thiazole derivatives

This invention provides compounds of formula IA or IB: wherein HY, R, R, G, W, n, and A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders. 

This invention provides compounds of formula IA or IB: wherein HY, R, R, and G, are as described in the specification. The compounds are inhibitors of VPS34 and/or PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

This invention provides compounds of formula IA-a or IB-a and subsets thereof: wherein Z, HY, R, R, G, W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

This invention provides compounds of formula IA-i-a or IB-i-a and subsets thereof: wherein Z, HY, R, R, R, G, W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

This invention provides compounds of formula I-A or I-B: wherein HY, G, G, R, R, W, W, n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Provided is a fused heterocycle derivative showing a strong Raf inhibitory activity. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Heterocyclic compound and use thereof

The present invention provides a heterocyclic compound having a strong Raf inhibitory activity, which is represented by the following formula wherein each substituent is as defined in the present specification, or a salt thereof.

Provided is a heterocyclic compound showing strong Raf inhibitory activity. A compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Benzothiazole compounds useful for Raf inhibition

A protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus; a gene coding this protein; a mutant of this gene; a vector carrying the mutant gene; a yeast strain belonging to the genushaving been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced, are described.

Process for producing protein with reduction of acidic sugar chain and glycoprotein produced thereby

A gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genusis described. Also described is a means of suppressing a functional product encoded by the gene.

A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; is, for example, the formula: 

Quinoxalinone derivatives

Growing community of inventors

Kanagawa, Japan

Masaaki Hirose